Arrowhead Pharmaceuticals announced that its Phase 3 clinical trials evaluating plozasiran in patients with severe hypertriglyceridemia successfully met all primary endpoints. According to the company statement, the SHASTA-3 and SHASTA-4 studies demonstrated statistically significant reductions in fasting triglycerides among participants receiving the investigational RNA interference therapeutic.
Phase 3 SHASTA-3 and SHASTA-4 Trial Design
The randomized, double-blind, placebo-controlled trials assessed the efficacy and safety profile of plozasiran in adults diagnosed with severe hypertriglyceridemia, a condition characterized by severely elevated triglyceride levels that significantly increase the risk of acute pancreatitis. Arrowhead Pharmaceuticals designed the multi-center trials to measure percentage changes in fasting triglycerides from baseline compared to a placebo group. Investigators administered subcutaneous injections of plozasiran at predetermined intervals over the study period to evaluate lipid-lowering sustained activity.
Clinical Impact on Severe Hypertriglyceridemia
Severe hypertriglyceridemia often proves difficult to manage with conventional lifestyle interventions and standard lipid-lowering therapies alone. Plozasiran targets the apolipoprotein C-III (APOC3) messenger RNA, effectively silencing the gene expression to reduce APOC3 protein production in the liver. According to clinical data shared by Arrowhead Pharmaceuticals, inhibiting APOC3 clears triglycerides from the bloodstream more efficiently, lowering the dangerous threshold associated with acute pancreatitis episodes.
Next Steps for Regulatory Submission
Following the completion of the SHASTA-3 and SHASTA-4 trials, Arrowhead Pharmaceuticals intends to compile comprehensive safety and efficacy datasets for global regulatory submissions. Company executives noted that the positive Phase 3 results serve as a foundation for upcoming marketing applications with health authorities, paving the way for potential commercial availability of plozasiran for patients lacking adequate treatment options.
Worth a look